• Markets
    • icon
  • Companies
NSB · ASX

Neuroscientific Biopharmaceuticals Ltd. (ASX:NSB)

AU$0.039

 -0.004 (-9.302%)
ASX:Live
26/07/2024 03:22:54 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NSB Overview

NSB Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NSB

Website

Neuroscientific Biopharmaceuticals Ltd.

Telephone

N/A

Address

Description

N/A

NSB Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.12

Trade Value (12mth)

AU$3,231.00

1 week

7.5%

1 month

19.44%

YTD

-2.27%

1 year

-62.61%

All time high

0.54

Key Fundamentals

EPS 3 yr Growth

-79.800%

EBITDA Margin

N/A

Operating Cashflow

-$2m

Free Cash Flow Return

-45.10%

ROIC

-20.90%

Interest Coverage

N/A

Quick Ratio

8.40

Other Data

Shares on Issue (Fully Dilluted)

145m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

NSB Announcements

Latest Announcements

Date Announcements

19 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

10 July 24

Notice of Release of Escrowed Securities

×

Notice of Release of Escrowed Securities

11 June 24

NSB Completes PRE-IND Meeting with US FDA on EmtinB

×

NSB Completes PRE-IND Meeting with US FDA on EmtinB

29 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

08 April 24

Notification of cessation of securities - NSB

×

Notification of cessation of securities - NSB

02 April 24

Appointment of Executive Director & FDA Pre-Ind Meeting

×

Appointment of Executive Director & FDA Pre-Ind Meeting

20 March 24

NSB Receives A$2.2M Research & Development Tax Refund

×

NSB Receives A$2.2M Research & Development Tax Refund

27 February 24

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

06 February 24

Company Secretary Appointment/Resignation

×

Company Secretary Appointment/Resignation

31 January 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

15 January 24

Notification of cessation of securities - NSB

×

Notification of cessation of securities - NSB

27 December 23

Expiry of Options

×

Expiry of Options

07 December 23

Final Director's Interest Notice - Rennie

×

Final Director's Interest Notice - Rennie

05 December 23

Changes to NSB Board

×

Changes to NSB Board

05 December 23

Initial Director's Interest Notice - Keating

×

Initial Director's Interest Notice - Keating

05 December 23

Final Director's Interest Notice - Quantrill

×

Final Director's Interest Notice - Quantrill

01 December 23

Resignation of CEO

×

Resignation of CEO

30 November 23

Chair's address to shareholders & AGM presentation

×

Chair's address to shareholders & AGM presentation

30 November 23

Results of Meeting

×

Results of Meeting

27 November 23

Notice of Annual General Meeting - Withdrawal of Resolutions

×

Notice of Annual General Meeting - Withdrawal of Resolutions

21 November 23

Notification of cessation of securities - NSB

×

Notification of cessation of securities - NSB

21 November 23

Initial Director's Interest Notice - Ntoumenopoulos

×

Initial Director's Interest Notice - Ntoumenopoulos

21 November 23

Initial Director's Interest Notice - Barlow

×

Initial Director's Interest Notice - Barlow

16 November 23

Addendum to Notice of Meeting

×

Addendum to Notice of Meeting

14 November 23

Further information on changes to Board

×

Further information on changes to Board

NSB Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.07 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.07 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 39.3 -227.5 89.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.02 -0.06 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.05 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 41.2 -262.1 91.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.5 -26.9 -20.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.10 0.04 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.10 0.04 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 141.0 -63.5 -14.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 143 143 143 Lock Lock Lock
Basic m Lock Lock Lock Lock 143 143 143 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 4 10 6 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -8.4 -5.7 10.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -4 -10 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.3 -150.8 41.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -4 -11 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -43.6 -148.7 41.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -3 -10 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -3 -10 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -10.8 -228.4 89.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -3 -7 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 14 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -3 -7 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -15.2 -164.0 66.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 14 7 5 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 15 8 5 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -14 -7 -5 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 2 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 15 6 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 15 6 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 300.2 -62.2 -15.0 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -21.4 -134.9 -20.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -21.8 -189.1 -22.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -46.3 -104.4 -119.9 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -34.8 -103.7 -20.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -28.5 -69.0 -45.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.4 0.7 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -97.0 -130.7 -104.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 64.6 3.3 8.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 64.6 3.3 8.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.2 97.5 98.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -1,164.5 -313.0 -385.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -21.4 -134.9 -20.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.4 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -21.8 -189.1 -22.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -21.8 -189.1 -22.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 705.3 6,588.4 8,669.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -705.3 -6,588.4 -8,669.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NSB Shortsell

Frequently Asked Questions

The current share price of Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is AU$0.039.
The 52-week high share price for Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is AU$0.12.
The 52-week low share price for Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX)? is AU$0.03.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) does not pay a dividend.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) does not pay a dividend.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) does not offer franking credits.
Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is classified in the Healthcare.
The current P/E ratio for Neuroscientific Biopharmaceuticals Ltd. (NSB:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.